Résumé
Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary data obtained in a small series of patients were encouraging and this strategy might become an alternative treatment in those patients with a druggable mutation that induces a stimulation of the MAP kinase pathway. This is an active field of research to answer many still unresolved questions.
langue originale | Anglais |
---|---|
Pages (de - à) | T179-T191 |
journal | Endocrine-Related Cancer |
Volume | 28 |
Numéro de publication | 10 |
Les DOIs | |
état | Publié - 1 oct. 2021 |